Sudeep Pharma Q2 FY26 – Modest Revenue Growth, Profitability Under Pressure

Sudeep Pharma reported a mixed September 2025 quarter, with marginal YoY growth in revenue, while operating profit and net earnings saw a decline, indicating margin pressure. • Sales: ↑ 9% YoY to ₹163 crore (vs ₹149 crore in Sep 2024) • EBIDT: ↓ 13% YoY to ₹55.5 crore (vs ₹63.5 crore) • Net Profit: ↓ 6% YoY to ₹46.8 crore (vs ₹48.8 crore) At a price of ₹687, market cap ₹7,762 crore, and PE 57.2, Sudeep Pharma continues to maintain healthy revenues, though profitability remains under pressure due to cost and margin challenges.